$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914057161 Filed on August 06, 2014

Income Statement

Concept	2014 Q2	2013 Q4	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.870M	$5.970M	$4.750M
YoY Change	4.38%	40.47%	30.14%
% of Gross Profit
Research & Development	$14.94M	$9.630M	$12.10M
YoY Change	22.22%	-16.91%	111.97%
% of Gross Profit
Depreciation & Amortization	$170.0K	$200.0K	$180.0K
YoY Change	13.33%	33.33%	28.57%
% of Gross Profit
Operating Expenses	$22.82M	$15.59M	$16.84M
YoY Change	15.41%	-1.58%	80.07%
Operating Profit	-$22.82M	-$15.59M	-$16.84M
YoY Change	175.92%	-1.54%	80.07%
Interest Expense	$595.0K	-$590.0K	$525.0K
YoY Change	-6.3%	-255.26%	136.49%
% of Operating Profit
Other Income/Expense, Net	$175.0K	-$40.00K	$0.00
YoY Change
Pretax Income	-$23.22M	-$16.21M	-$17.33M
YoY Change	162.3%	4.85%	84.68%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$23.22M	-$16.21M	-$17.33M
YoY Change	162.25%	4.94%	84.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$591.3K	-$413.6K	-$463.5K
COMMON SHARES
Basic Shares Outstanding	39.27M shares	39.11M shares	37.39M shares
Diluted Shares Outstanding	39.27M shares		37.39M shares

Balance Sheet

Concept	2014 Q2	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.70M	$113.9M	$128.0M
YoY Change	7.68%	22.6%	42.7%
Cash & Equivalents	$82.70M	$113.9M	$128.0M
Short-Term Investments
Other Short-Term Assets	$4.000M	$2.300M	$1.700M
YoY Change	122.22%	283.33%	183.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$86.70M	$116.2M	$129.7M
YoY Change	10.35%	24.13%	43.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.778M	$1.812M	$1.904M
YoY Change	151.47%	8.76%	19.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$300.0K	$100.0K
YoY Change	300.0%	200.0%	0.0%
Total Long-Term Assets	$63.41M	$60.34M	$60.21M
YoY Change	5.4%	0.59%	-3.05%
TOTAL ASSETS
Total Short-Term Assets	$86.70M	$116.2M	$129.7M
Total Long-Term Assets	$63.41M	$60.34M	$60.21M
Total Assets	$150.1M	$176.5M	$190.0M
YoY Change	8.21%	14.94%	24.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.41M	$5.929M	$4.661M
YoY Change	44.39%	-16.02%	55.37%
Accrued Expenses	$4.546M	$3.905M	$5.652M
YoY Change	42.6%	33.14%	109.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.281M	$3.283M	$7.055M
YoY Change	-30.19%	9.18%	907.86%
Total Short-Term Liabilities	$21.82M	$16.46M	$19.82M
YoY Change	20.53%	4.5%	204.95%
LONG-TERM LIABILITIES
Long-Term Debt	$16.49M	$16.34M	$12.54M
YoY Change	10.74%	0.72%	45.79%
Other Long-Term Liabilities	$300.0K	$400.0K	$400.0K
YoY Change	-40.0%	-33.33%	-42.86%
Total Long-Term Liabilities	$16.49M	$16.34M	$12.54M
YoY Change	10.74%	0.72%	34.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.82M	$16.46M	$19.82M
Total Long-Term Liabilities	$16.49M	$16.34M	$12.54M
Total Liabilities	$38.56M	$33.17M	$32.83M
YoY Change	16.87%	1.51%	107.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$429.1M	-$391.6M	-$375.4M
YoY Change		16.71%
Common Stock	$393.0K	$391.0K	$391.0K
YoY Change		24.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$111.5M	$143.3M	$157.1M
YoY Change
Total Liabilities & Shareholders Equity	$150.1M	$176.5M	$190.0M
YoY Change	8.21%	14.94%	24.56%

Cashflow Statement

Concept	2014 Q2	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$23.22M	-$16.21M	-$17.33M
YoY Change	162.25%	4.94%	84.68%
Depreciation, Depletion And Amortization	$170.0K	$200.0K	$180.0K
YoY Change	13.33%	33.33%	28.57%
Cash From Operating Activities	-$17.93M	-$14.05M	-$16.29M
YoY Change	250.88%	57.51%	77.26%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	-$120.0K	-$220.0K
YoY Change	72.73%	-29.41%	1000.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$2.160M
YoY Change		-100.0%
Cash From Investing Activities	-$570.0K	-$110.0K	$1.930M
YoY Change	72.73%	-100.25%	-6533.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$67.00M
YoY Change			160.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	40.00K	67.79M
YoY Change	-110.0%	-99.61%	164.49%
NET CHANGE
Cash From Operating Activities	-17.93M	-14.05M	-16.29M
Cash From Investing Activities	-570.0K	-110.0K	1.930M
Cash From Financing Activities	-60.00K	40.00K	67.79M
Net Change In Cash	-18.56M	-14.12M	53.43M
YoY Change	283.47%	-130.83%	225.59%
FREE CASH FLOW
Cash From Operating Activities	-$17.93M	-$14.05M	-$16.29M
Capital Expenditures	-$570.0K	-$120.0K	-$220.0K
Free Cash Flow	-$17.36M	-$13.93M	-$16.07M
YoY Change	263.18%	59.2%	75.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39256000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31754000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39273000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37522000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8854000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31754000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22532000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31654000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31654000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2014Q2	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	2882000	USD
CY2013Q4	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	2484000	USD
CY2014Q2	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	516000	USD
CY2013Q4	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	1220000	USD
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	669000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	24000	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	155000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4546000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3905000	USD
CY2014Q2	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2014Q2	insm	Additional Charge At End Of Term AdditionalChargeAtEndOfTerm	266000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	59788	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4732947	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	827113	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.94
CY2014Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	247000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.42
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.22
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.86
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.29
CY2014Q2	insm	Unamortized Discount From Warrant UnamortizedDiscountFromWarrant	244000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.37
CY2014Q2	us-gaap	Debt Current DebtCurrent	3281000	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16494000	USD
CY2014Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7430000	USD
CY2014Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	12570000	USD
CY2014Q2	us-gaap	Long Term Debt LongTermDebt	20000000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	insm	Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption	900000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39276389	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M1D
CY2013Q3	us-gaap	Share Price SharePrice	10.40
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39276389	shares
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y25D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	48601000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	46057000	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12083000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	159000	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	324000	USD
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2014Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	323222	shares
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5151000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82697000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4389000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1221000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q4	insm	Unrecognized Tax Benefits Reserves UnrecognizedTaxBenefitsReserves	0	USD
CY2014Q2	insm	Unrecognized Tax Benefits Reserves UnrecognizedTaxBenefitsReserves	0	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	680000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1106000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1144000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	741000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	762000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	718000	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16338000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	38562000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	33174000	USD
CY2013Q4	insm	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	1	item
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	32099	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.27
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3632996	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5058459	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1517350	shares
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4778000	USD
CY2014Q2	us-gaap	Assets Assets	150110000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113894000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2269000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	116163000	USD
CY2013Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2013Q4	us-gaap	Other Assets OtherAssets	323000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1812000	USD
CY2013Q4	us-gaap	Assets Assets	176498000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11407000	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2071000	USD
CY2014Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	314000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	167000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	32000	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	3281000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21818000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5929000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2839000	USD
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	307000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	129000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	64000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3283000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16456000	USD
CY2014Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	250000	USD
CY2013Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	380000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	393000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	540298000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-429143000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8269000	USD
CY2013Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	50000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	635000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8854000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8854000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	391000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	534554000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391621000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	111548000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	143324000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150110000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	176498000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39137679	shares
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14942000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7874000	USD
CY2014Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	12000	USD
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39137679	shares
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	22816000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23224000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23224000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22816000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39273000	shares
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	19769000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12225000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7544000	USD
CY2013Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	11500000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31754000	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26293000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14602000	USD
	us-gaap	Operating Expenses OperatingExpenses	40895000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40895000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	29000	USD
	us-gaap	Interest Expense InterestExpense	1201000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-41911000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37522000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39256000	shares
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	11500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22559000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11520000	USD
	us-gaap	Operating Expenses OperatingExpenses	34079000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22579000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	101000	USD
	us-gaap	Interest Expense InterestExpense	1277000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23753000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22532000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31654000	shares
	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	us-gaap	Interest Paid InterestPaid	944000	USD
	us-gaap	Accretion Expense AccretionExpense	97000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-491000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	59000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	677000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	618000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16194000	USD
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39283016	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	342000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5336000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	192000	USD
	us-gaap	Accretion Expense AccretionExpense	62000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1843000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3642000	USD
	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	103000	USD
	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-123000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-768000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30579000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	895000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-895000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	409000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	277000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31197000	USD
	us-gaap	Interest Paid InterestPaid	930000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4389000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	236000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74588000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90782000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1221000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	175000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	595000	USD
CY2014Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2013Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	156000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
CY2013Q2	insm	Fair Value Of Warrants Outstanding FairValueOfWarrantsOutstanding	790000	USD

Files In Submission

Name	View Source	Status
0001104659-14-057161-index-headers.html	Edgar Link	pending
0001104659-14-057161-index.html	Edgar Link	pending
0001104659-14-057161.txt	Edgar Link	pending
0001104659-14-057161-xbrl.zip	Edgar Link	pending
a14-14157_110q.htm	Edgar Link	pending
a14-14157_1ex31d1.htm	Edgar Link	pending
a14-14157_1ex31d2.htm	Edgar Link	pending
a14-14157_1ex32d1.htm	Edgar Link	pending
a14-14157_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
insm-20140630.xml	Edgar Link	completed
insm-20140630.xsd	Edgar Link	pending
insm-20140630_cal.xml	Edgar Link	unprocessable
insm-20140630_def.xml	Edgar Link	unprocessable
insm-20140630_lab.xml	Edgar Link	unprocessable
insm-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2014 Q2 Form 10-Q Financial Statement

#000110465914057161 Filed on August 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2014 Q2 Form 10-Q Financial Statement

#000110465914057161 Filed on August 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm